Goodwin Procter advised Palleon Pharmaceuticals on the deal. Palleon Pharmaceuticals announced its strategic collaboration agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize two bifunctional...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here